US chip suppression won’t stop Chinese industries’ development, will only make them stronger: China chip trade group
By Zhang Yiyi and Wang Cong | Global Times | December 13, 2024
On December 3, one day after the US government announced yet another round of restrictions on chip sales to Chinese firms, four Chinese industry associations, including the China Semiconductor Industry Association (CSIA) and the Internet Society of China (ISC), issued firmly worded statements declaring that US chip products are no longer safe and reliable.
Behind the strongly-worded statements are the profound indignation among Chinese industries over the US government’s relentless campaign to target an ever-growing number of Chinese companies, and the determination to ensure safe and reliable chip supplies for relevant Chinese industries, according to Wei Shaojun, vice chairman of the CSIA.
“The US government has repeatedly suppressed Chinese semiconductor companies, and CSIA members have been very outraged about this. So, it is the CSIA’s responsibility to speak out,” Wei told the Global Times in an interview on Thursday, noting that more than 240 Chinese semiconductor companies have been added to the US’ so-called Entity List so far, accounting for one-quarter of the CSIA members, or one-third, if affected foreign CSIA members are included.
In the statement on December 3, the CSIA blasted the US government’s latest move of adding more than 140 Chinese firms to its so-called Entity List, saying the US arbitrary export control measures against Chinese firms have affected the stable supply of US chip products. “US chip products are no longer safe and reliable and relevant Chinese industries will have to be cautious in purchasing US chips,” it said.
Also making the same determination are three other Chinese industry associations that represent the main buyers of chips – the ISC, the China Association of Communications Enterprises, and the China Association of Automobile Manufacturers. Relevant Chinese ministries, including the Ministry of Commerce, also slammed the US move and vowed to take “necessary” measures to resolutely safeguard its legitimate rights and interests.
China’s innovation edge
The statements from the Chinese industry associations showed a “stronger-than-before attitude” and “they expressed our strong indignation,” Tu Xinquan, dean of China Institute for WTO Studies at the University of International Business and Economics and a consultant for the CSIA, told the Global Times.
As the US government is bent on escalating the crackdown measures, “we must take some necessary measures to firmly safeguard our legitimate rights and interests,” Tu said, “we must accordingly encourage and support the purchase of reliable and safe products, whether they are made by Chinese companies or in other countries or regions.”
For domestic internet companies, they need to “promptly adjust their foreign cooperation and development strategies,” Pei Wei, Deputy Secretary General of the ISC, told the Global Times in an interview. “They need to diversify the supply chain layout, especially for the procurement of key technologies and components, to reduce the reliance on a single source.”
Chinese internet companies should establish partnerships with chip manufacturers in countries and regions outside the US, strengthen support for domestic and locally produced chips, so as to diversify risks and enhance supply chain security and stability, Pei further noted.
“At the same time, we must also improve our internal capabilities and continue to build independent research and development, production and manufacturing capabilities,” Pei said.
Wei also urged support for reliable chip supplies in the face of the US’ relentless crackdown campaign.
“We call on the Chinese government to support the stable development of reliable semiconductor suppliers; we also call on semiconductor companies in relevant countries and regions to strive to become reliable semiconductor industry suppliers,” he said. “Suppression will not stop us from development. Chinese industries will become stronger and more confident in our development.”
Broader cooperation needed
In response to the US government’s relentless crackdown campaign, Chinese industries should also remain open for cooperation with their foreign counterparts, the leaders of the industries also said.
“The current success and achievement of the semiconductor industry are the result of global competition and cooperation. Closed development is not conducive to technological progresses and breakthroughs in the industry, and will harm the interests of global consumers,” Wei said, urging the US to return to the stage for fair competition.
Tu noted that it is the US government’s policies, not US companies, that make US chip products unsafe and unreliable. “The restrictions are on exports, so they are actually restrictions on US companies,” he said.
Pei of the ISC also called for principles of openness, inclusiveness and win-win results for international cooperation. “Chinese and foreign industries can conduct deep cooperation in areas such as research and development, market exploration and talent training to share the development results,” Pei said.
House Strikes a Blow To Censorship in Landmark Defense Bill Vote
By Dan Frieth | Reclaim The Net | December 16, 2024
A new chapter in the fight against censorship unfolded as the US House of Representatives approved the National Defense Authorization Act (NDAA) for fiscal year 2025. While 124 Democrats opposed the bill, its passage marked a significant step in addressing concerns over biased media practices and government spending.
Among its provisions, the legislation includes a prohibition on contracts with firms like NewsGuard Technologies, an organization criticized and accused of targeting certain media outlets.
Speaker of the House Mike Johnson praised the bill’s contents, highlighting its focus on accountability in government spending and ensuring a level playing field for media voices.
Founded in 2018, NewsGuard claims to serve as a nonpartisan fact-checking organization, rating the reliability of news websites. However, critics argue that its actions reveal a far different agenda. The group has been accused of systematically targeting certain outlets while shielding some publishers from scrutiny.
Its self-proclaimed mission to “promote truth” often directs readers to government-endorsed sources like the Centers for Disease Control and Prevention (CDC), a practice that raises questions about impartiality – especially since it has received funding from government sources.
Breitbart, The Drudge Report, and The Daily Mail are among the prominent outlets that have been ranked poorly by NewsGuard.
Reports indicate that the organization allegedly advises advertisers to avoid these sites, effectively stripping them of revenue. Critics see this as financial censorship—a strategy to silence dissenting voices while funneling resources toward establishment-backed media.
In recent years, these concerns have deepened, particularly following revelations that the US Department of Defense (DOD) awarded NewsGuard $749,387 in taxpayer funds in September 2021.
Biden Regime Launches Task Force on Chinese Censorship, Drawing Criticism for Hypocrisy
By Didi Rankovic – Reclaim The Net – December 16, 2024
The Biden-Harris administration has revealed it was setting up an action group to “monitor and address the effects” of any censorship or intimidation of Americans by China.
Signed by President Joe Biden, the memorandum addressed heads of executive departments and agencies, while the task force is to be led by the assistant to the president for National Security Affairs and the director of the National Economic Council.
This move comes after the administration spent the past four years doubling and tripling down on policies encouraging unprecedented censorship at home and being sued and investigated for colluding (through pressure via third parties) with social platforms and other tech companies to do its (unconstitutional) bidding.
Hypocrisy this may be, but that might be the least of the problems with this sudden spurt of activity by an administration that is weeks away from exiting, stage left.
If we choose to forget that many of the censorship and surveillance mechanisms that permeated the soon-to-be former administration’s activities were regularly mentioned by critics as “inspired” by those used by China’s authorities, the question remains: why establish an entirely new “task force” and why now?
The departments and agencies that will be represented at assistant secretary or above level include the departments of state, defense, treasury, commerce, agriculture, education, the Department of Homeland Security, the CIA, the FBI, the director of National Intelligence, etc. – plus, “other agencies and offices as the President may, from time to time, designate.”
Opponents of the Chinese authorities and their notorious brand of censorship welcome the move and believe it should be endorsed by the incoming Trump administration, but also – somehow – expanded to China itself.
Declarative statements about the purpose of such “monitoring” outfits are one thing, but recent history shows how far those can veer off course.
One cautionary tale is the Department of Homeland Security’s Global Engagement Sector (GEC) which was set up to direct, lead, and coordinate US government efforts countering foreign state propaganda and disinformation.
What that turned out to be, however, is a weapon of censorship pointed at Americans, that used third parties to circumvent legal constraints and push biased, partisan narratives at home.
West pushing Russia beyond ‘red line’ – Putin
RT | December 16, 2024
The West’s support for Ukraine is pushing Russia to the point where it cannot help but retaliate, President Vladimir Putin has said, while warning the US against deploying medium-range missiles.
Speaking at a meeting of top Russian Defense Ministry officials on Monday, Putin accused the US of seeking “to weaken our country and inflict a strategic defeat” on Moscow by continuing “to pump a de facto illegitimate ruling regime in Kiev with weapons and money, sending mercenaries and military advisers, thereby encouraging further escalation of the conflict.”
Washington is instilling fear in Americans by resorting to “simple tactics,” Putin stated. “They push us to the red line… we begin to respond, and then they frighten their population,” he added, suggesting that the US used the same approach during its rivalry with the Soviet Union.
The Russian president also slammed the West for what he described as attempts to impose its own rules on the rest of the world while waging “hybrid wars” against anyone who resists, including Russia.
In this vein, NATO is boosting its defense spending and forming “strike groups” near Russia’s borders, he added. “The number of American service members in Europe has already exceeded 100,000 troops,” he noted.
NATO is ramping up its presence not only in Europe but also in regions that have never seen this type of military footprint, particularly the Asia-Pacific, Putin said, voicing particular concerns over US plans to deploy missile systems with a range of up to 5,500km.
Putin was referring to a type of weapon previously banned by the Cold War-era Intermediate-Range Nuclear Forces (INF) Treaty. The US unilaterally pulled out of the treaty in 2018, citing Russian non-compliance – an allegation Moscow has denied.
The Russian president stressed that despite Washington’s withdrawal from the INF Treaty, Moscow made a unilateral and voluntary commitment not to deploy medium- and short-range missiles unless the US deploys such weapons anywhere in the world.
However, “if the United States begins to deploy such systems, then all our voluntary restrictions will be lifted,” Putin warned.
FDA Advisers Bullish on RSV Shots for Kids, Even as Safety Signals Shut Down Moderna Trials
By Brenda Baletti, Ph.D. | The Defender | December 13, 2024
Advisers to the U.S. Food and Drug Administration (FDA) met Thursday to discuss the future of pediatric respiratory syncytial virus (RSV) vaccines after Moderna was forced to abruptly halt clinical trials for its mRNA RSV vaccine in children ages 5-23 months.
Clinical trial data released earlier this week in an FDA briefing document showed that rather than preventing RSV disease in small children, Moderna’s vaccine likely caused higher rates of severe RSV illness in its Phase 1 clinical trial.
Moderna halted the trial in July after it was informed that two babies in the vaccine group had developed severe RSV disease. The company didn’t publicly announce that the trial was discontinued until September.
The data presented Thursday at the Vaccines and Related Biological Products Advisory Committee meeting showed that 12.5% of vaccinated children developed severe RSV disease as compared to just 5% of children in the placebo group.
Among the children who developed symptomatic RSV disease, 26.3% in the vaccinated group progressed to severe disease, while only 8.3% of those in the placebo group did.
These results were concerning given the history of past attempts to develop an RSV vaccine for infants. In the 1960s, an experimental formalin–inactivated RSV vaccine for children led to two toddler deaths, and 80% of vaccine recipients required hospitalization for severe RSV.
The illnesses were attributed to vaccine-associated enhanced respiratory disease (VAERD) — a phenomenon that occurs when vaccination promotes immune responses that exacerbate the disease caused by subsequent infection with the pathogen the vaccine was meant to protect against.
In light of that history, and because the mechanisms that cause VAERD are still largely unknown, the FDA convened the advisory committee to discuss the implications of Moderna’s trial outcomes for other pediatric RSV vaccines.
The committee did not vote on Thursday or make any formal recommendations. Members watched presentations from consultants, the FDA, and pharmaceutical companies and discussed the risks and benefits of developing RSV vaccines for children.
They also commended Moderna for reporting its results and the existing clinical safeguards for recognizing early safety signals in pediatric RSV trials.
Vaccine makers developing 26 different RSV vaccines or monoclonal antibodies
The briefing document stated that the FDA was halting enrollment for all investigational trials for RSV vaccines for infants and toddlers under age 2 and children ages 2 through 5 who haven’t previously had RSV.
The FDA clarified at the outset of the meeting that the hold does not apply to vaccine candidates that use live attenuated vaccines, because there is no evidence that vaccines developed on this platform cause VAERD.
Advisers seemed to agree, except for Dr. Karen Kotloff who voiced concerns there was not enough information to assume that live attenuated vaccines don’t carry the same potential risk.
Dr. Pedro Piedra, who presented on clinical and non-clinical aspects of RSV vaccine safety shared a slide listing RSV vaccines and monoclonal antibodies currently in trials.
There are five pediatric vaccines other than Moderna’s — which Moderna’s Christine Shaw, Ph.D., definitively stated is no longer moving forward — in the pipeline. Four of them are for live-attenuated vaccines.
Vaccine makers are developing 26 different RSV vaccines or monoclonal antibodies for all age groups, all vying to enter a rapidly expanding market.
PR Newswire projected in 2023 the global RSV vaccine and antibody market would be worth $2.61 billion dollars in 2024 and rise to $13.59 billion by 2030.
Piedra — who began his presentation with the quick disclosure that he has grants for RSV prevention research from GSK, Icosavax and Merck and is a paid consultant in the field for Merck, Moderna, Pfizer and Sanofi — presented an optimistic picture of RSV vaccine development, citing protection offered by recently approved maternal vaccines and monoclonal antibodies.
Moderna’s results did raise some platform-specific concerns, Piedra conceded.
He listed the types of safety concerns that could be associated with different vaccine platforms — febrile seizures with adjuvanted or high-dose vaccines or when RSV vaccines are co-administered with other vaccines, autoimmunity that could be associated with new adjuvants, respiratory issues with intranasal vaccines, and systemic illnesses with vector-based or mRNA vaccines.
‘Unmet need’ as justification to push for more RSV vaxes for small children
Presenters repeatedly stated that there was an “unmet need” for pediatric RSV vaccines, especially for children between 8 months and 2 years old.
RSV usually causes mild cold-like symptoms, but in some cases can lead to hospitalization and death in infants and the elderly. By age 2, 97% of all babies have been infected with RSV, which confers partial immunity, making any subsequent episodes less severe.
The disease burden for infants can be serious. In the U.S., RSV infection is the leading cause of infant hospitalization among those younger than 6 months, although a very small percentage of children with the virus will die.
An FDA representative said the Centers for Disease Control and Prevention (CDC) estimates that 100-200 infants die per year from the disease. However, internist Dr. Meryl Nass told The Defender that even those low numbers may overestimate mortality.
Nass pointed to a CDC study analyzing RSV deaths in infants between 2005 and 2016 and found a total of 314 deaths in children under age 1, or 25 on average per year, Nass reported. Only 17 of those deaths per year listed RSV as the underlying cause of death.
The FDA also said that maternal vaccines and monoclonal antibodies had begun to reduce those numbers, but emphasized there is still an “unmet need” for a vaccine for children going into their second RSV season — even as it presented data showing hospitalizations in that season are lower.
Moderna said this “unmet need” drove them to develop their failed vaccine. A Sanofi representative, who gave an update on their live-attenuated RSV virus, said the company sought to meet that “unmet need” for children in their second RSV season.
Sanofi also sells nirsevimab — brand name Beyfortus — the monoclonal antibody shot the CDC recommends for all newborns to protect them in their first RSV season.
Sanofi and the National Institutes of Health (NIH) are collaborating on the live-attenuated virus vaccine platform. The NIH developed 16 different vaccine candidates that it trialed in children and currently has one SP-125 in Phase 3 clinical trials.
These vaccines have not shown VAERD after one season of surveillance, the Sanofi representative said. The safety trials showed no safety concerns and SP-125 is currently being tested for efficacy in toddlers 6-22 months of age, but it is not yet fully enrolled.
During the “public comments” section of the meeting, three other vaccine makers promoted their vaccines to the committee.
Goal is more RSV shots for kids to provide passive immunity followed by ‘active immunity’
FDA asked the committee members to discuss existing evidence on whether infants and toddlers could eventually get sequential administration of RSV monoclonal antibodies followed by RSV vaccines.
That would mean even more shots on the childhood immunization schedule. The monoclonal antibodies or maternal vaccination would provide babies with “passive immunity” — antibodies to fight the virus that weren’t created by their own immune systems.
Then, in this schema, a two- or three-shot course of an RSV vaccine could protect babies from RSV in the second season, giving them “active immunity.”
Most committee members said more data were necessary to evaluate the safety of such a plan, but they generally agreed that it was a good direction to move in.
Watch the meeting here.
This article was originally published by The Defender — Children’s Health Defense’s News & Views Website under Creative Commons license CC BY-NC-ND 4.0. Please consider subscribing to The Defender or donating to Children’s Health Defense.
RFK Jr. and the Samoan Measles Outbreak
By David Marks | Brownstone Institute | December 15, 2024
When the nomination of Robert F. Kennedy, Jr. as Health and Human Services Secretary comes before the Senate, the specter of the Samoan measles outbreak of 2019 will dramatically be invoked to challenge him. Kennedy’s critics have repeatedly relied on this topic, citing stories that claim he was responsible for an epidemic in 2019 that caused at least 83 children to die due to vaccine hesitancy. In recent articles, reporters quote previous news coverage relying on unsubstantiated and minimal data to justify their analysis.
These stories repeat dubious assertions, fail to discuss any pathological analysis, and dismiss Kennedy’s considered support of healthcare in Samoa. He had assisted the Samoan government in developing a system for health officials to assess the efficacy and safety of medical interventions or drugs, including vaccines.
In November 2019, while the deaths of Samoan children were rapidly increasing, Kennedy wrote a comprehensive letter to the Samoan Prime Minister, presenting some possible causes of the unprecedented, virulent outbreak of measles. His concerns about the epidemic in Samoa highlight striking anomalies that were apparent to a few investigators at the time, although they remain unexplained.
The most convenient and generally accepted explanations of the outbreak claim the epidemic was the result of hesitancy, causing the population to be under-vaccinated. Measles vaccination rates were low due to the previous deaths of two infants given improperly formulated injections, which had nothing to do with Kennedy’s views.
Any considered analysis of the accessible facts soundly contradicts the conjecture that the high death count was related to low vaccination rates.
In most measles epidemics, mortality is on average one in one thousand, and dying children are often malnourished or immunocompromised. From October through December of 2019, over one in a hundred Samoan children with the disease died, ten times more than any previous outbreak in the world. No accounting for this overt statistical deviance has been published.
Despite the presumptions of those who attack Kennedy, there was never any investigation into any aspect of this baffling tragedy. Edwin Tamasese, a health advocate who questioned Samoan government policies during the outbreak, gave Kennedy some insight into what was happening.
Tamasese was concerned about the number of sick and dying Samoan children and began to assist families whose children were severely ill. He and his colleagues encountered conditions that contradicted the government’s narrative.
While the press condemned him as an anti-vaxxer, Tamasese’s interventions and observations are revelatory. In an interview after the outbreak subsided, he said, “We were very careful to take statistics when we were going in to try to identify trends. When we assessed our numbers, 98 percent of those who were getting ill had been vaccinated consistently six to seven days prior to illness. The excuse was that the vaccine did not have time to become effective. However, according to an immunologist on the team, the six to seven-day period was also the length of time it would take an under-attenuated vaccine to make the recipient sick.”
Doctors in hospitals also reported that the very ill and dying children did not have symptoms consistent with normal cases of measles. When the outbreak began, blood from the first thirty-nine cases had been sent to Australia; only seven samples were positive for measles.
The government stopped testing to confirm the cause of these deaths in early November 2019. Without scientific confirmation, illness and mortality were attributed to low immunization rates. Samoan health authorities continued to claim that the only remedy for the deadly epidemic was a drive to increase vaccination; however, the campaign appeared to increase the number of measles cases.
Neighboring Pacific island countries, Tonga and Fiji, which had concurrent outbreaks of the virus — and had a different source of the measles vaccine — did not suffer the same dramatic mortality rates. This should have raised concerns, yet there hasn’t been an inquiry into why the Samoan government switched vaccine sourcing from India to Belgium midway through the crisis.
A renewed effort to vaccinate with this alternate supply began in the first week of December 2019; it was hailed as the reason the outbreak subsided. Measles vaccines take at least 10 days before creating an immune response. There has been no explanation for the data confirming that the onset of cases dropped dramatically two weeks before this vaccination drive could have had any effect.
The government response was not driven by factual analysis; the effort focused on promoting the vaccine and silencing those questioning authority.
With Samoan officials and the press deriding his work and views, Tamasese was arrested and charged with incitement of a government order and treating children without a license. Although this was deemed appropriate justice by the international news media as they echoed the government’s praise of the vaccine, reporters again failed to present the questions raised by the outbreak.
The prosecution’s primary witness against Tamasese was a nurse whose child had measles. He had suggested that administering vitamins A and C could be helpful — and standard medical treatment for measles patients. She had taken his advice and admitted that her child recovered soon afterward.
Tamasese reported that when the nurse left the courtroom, the judge, in throwing out the case, said, “That witness may as well have represented the accused.” There was relative silence from the news media when all charges against him were dismissed.
While worldwide attention on Samoa ignored dramatic inconsistencies, Kennedy was one of the few people who asked detailed and important questions. His views were marginalized; it was easier and politically correct to blame the tragedy on low rates of vaccination.
The relatively few details known about the Samoan measles outbreak indicate that forces intent on presenting vaccines as an infallible, unquestionable remedy will not tolerate scrutiny or admit failures. This continuing devious tactic is applied internationally and is eagerly supported by most governments and the press.
Analysis of the Covid-19 pandemic has only recently vindicated those who were scorned for questioning the response. The parallels to the unfolding of the epidemic in Samoa are not obscure, and support Kennedy’s contention that vaccine development, manufacturing, and application need much more effective evaluation and monitoring to prevent complications and death.
When the US government assures the public that any vaccine or medication is safe and effective, this must come from an independent, thorough, and transparent process, rather than relying only on the words and actions of those with vested interests.
The current criticism of Kennedy is an endeavor to make him look dangerously ignorant and irresponsible to sway members of the Senate. Much to the chagrin of those who vilify him, his efforts to understand and assist in the Samoan measles outbreak exemplify his thoughtfulness and capabilities.
RFK, Jr. is at the forefront of healthcare oversight; his confirmation as HHS Secretary will ensure that Americans benefit from his experience and knowledge.
USS Harry S. Truman Leads American Naval Deployment to Middle East
Sputnik – 15.12.2024
The USS Harry S. Truman Carrier Strike Group arrived in the Middle East on December 14, entering the US Central Command’s (CENTCOM) area of responsibility. The deployment was announced by CENTCOM on the social media platform X.
The group includes the aircraft carrier USS Harry S. Truman, Carrier Air Wing 1 with nine aviation squadrons, the guided-missile cruiser USS Gettysburg (Ticonderoga class), and two guided-missile destroyers, USS Stout and USS Jason Dunham (Arleigh Burke class).
Earlier in November, US F-15E Strike Eagle fighter jets were deployed to the region from the United Kingdom, reinforcing the American military presence in the Middle East.
The deployment comes amid heightened regional tensions and US President-elect Donald Trump’s earlier remarks promising to avoid “starting wars” once he officially takes office.
Global Majority nations are de-dollarizing trade with Panda Bonds and African banks
Inside China Business | December 13, 2024
Top African banks are key in the BRICS push to do more trade outside the US Dollar, and especially outside Western systems. By setting up branches inside China, African banks are able to borrow and lend in renminbi, the Chinese currency. This allows for cross-border trades to be settled in local currencies and RMB, instead of through USD-denominated letters of credit or debt markets. Panda Bonds are another tool, rapidly gaining in popularity and usage. Pandas are RMB bonds, sold to investors in Mainland China who want to diversify their fixed income investments to global borrowers. To borrowers, Panda Bonds offer lower interest costs than USD- or Euro-denominated debt, while also allowing for repatriation and currency swaps that are common in USD loans. Africa’s biggest banks, including those owned by African governments themselves, have set up in Mainland China and are increasingly integrated into China’s financial and industrial sectors. And large Chinese banks are heading the other way, investing heavily in Africa’s raw materials industries, and providing liquidity for Africa’s rising consumer class.
Resources and links:
Substack, for video transcript and direct links https://open.substack.com/pub/kdwalms…
South China Morning Post, African banks set up shop in China as Beijing pushes for yuan to eclipse US dollar https://www.scmp.com/news/china/diplo…
Statista, China’s African Trade Takeover https://www.statista.com/chart/26668/…
Africa’s Top 100 Banks 2024: Going global https://african.business/2024/09/fina…
S&P Global, Three Minutes In Panda Bonds: Why Issuance Is Surging https://www.spglobal.com/ratings/en/r…


